对接受干扰素-α 2B 辅助治疗的皮肤恶性黑色素瘤患者的耐受性和治疗效果的回顾性分析:从社区肿瘤学的角度看问题。

Q3 Pharmacology, Toxicology and Pharmaceutics Journal of Experimental Therapeutics and Oncology Pub Date : 2017-09-01
Muhammad Zubair Afzal, Vani Pinnamaneni, K C Birendra, Alan T Davis, Tracy J Koehler, Nehal Lakhani
{"title":"对接受干扰素-α 2B 辅助治疗的皮肤恶性黑色素瘤患者的耐受性和治疗效果的回顾性分析:从社区肿瘤学的角度看问题。","authors":"Muhammad Zubair Afzal, Vani Pinnamaneni, K C Birendra, Alan T Davis, Tracy J Koehler, Nehal Lakhani","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Interferon alpha 2B (IFN-α) therapy in malignant melanoma has improved relapse free survival and overall survival but is considerably toxic and lowers the overall quality of life (QoL) substantially. A significant number of patients do not complete the full duration (one year) of therapy.</p><p><strong>Objective: </strong>The aim of this study was to evaluate patients' ability to tolerate IFN-α therapy and to compare our results to reported data in the literature.</p><p><strong>Methods: </strong>We conducted a retrospective review of patients diagnosed with cutaneous malignant melanoma who received IFN therapy after surgical resection. Patients were divided into two groups: patient who completed therapy (CIT) and those who did not (incomplete therapy, IIT). Duration of therapy was calculated. Reason for discontinuation and experienced side effects were reported. Statistical significance was determined at p &amp;#60; 0.05.</p><p><strong>Results: </strong>A total of 64 patients were included in the review. There were 16 (25%) patients were able to complete therapy. The most common reasons for discontinuing IFN-α therapy was fatigue (81.3%), fever (40.6%), depression (28.1%) and nausea (18.8%). Patients in the CIT group were younger than those in the IIT group (47.4 ± 14.2 vs 57.8 ± 11.9 years, mean ± SD; p = 0.011). There also seemed to be an association that those with the presence of advanced disease may have been more likely to complete therapy (node positive disease at the time of diagnosis, p = 0.07).</p><p><strong>Limitations: </strong>It is a retrospective study and has to rely on physician notes for the subjective data. For the survival analyses, the median follow-up times for both of the groups were less than 3.5 years.</p><p><strong>Conclusions: </strong>Younger patients were more likely to complete therapy. There was a trend towards an association between more advanced disease and the completion of therapy. Most common causes of discontinuation of therapy were fatigue, fever, depression, and nausea.</p>","PeriodicalId":45335,"journal":{"name":"Journal of Experimental Therapeutics and Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A retrospective analysis of tolerance and outcomes of cutaneous malignant melanoma in patients receiving adjuvant interferon-alpha 2B: a community oncology perspective.\",\"authors\":\"Muhammad Zubair Afzal, Vani Pinnamaneni, K C Birendra, Alan T Davis, Tracy J Koehler, Nehal Lakhani\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Interferon alpha 2B (IFN-α) therapy in malignant melanoma has improved relapse free survival and overall survival but is considerably toxic and lowers the overall quality of life (QoL) substantially. A significant number of patients do not complete the full duration (one year) of therapy.</p><p><strong>Objective: </strong>The aim of this study was to evaluate patients' ability to tolerate IFN-α therapy and to compare our results to reported data in the literature.</p><p><strong>Methods: </strong>We conducted a retrospective review of patients diagnosed with cutaneous malignant melanoma who received IFN therapy after surgical resection. Patients were divided into two groups: patient who completed therapy (CIT) and those who did not (incomplete therapy, IIT). Duration of therapy was calculated. Reason for discontinuation and experienced side effects were reported. Statistical significance was determined at p &amp;#60; 0.05.</p><p><strong>Results: </strong>A total of 64 patients were included in the review. There were 16 (25%) patients were able to complete therapy. The most common reasons for discontinuing IFN-α therapy was fatigue (81.3%), fever (40.6%), depression (28.1%) and nausea (18.8%). Patients in the CIT group were younger than those in the IIT group (47.4 ± 14.2 vs 57.8 ± 11.9 years, mean ± SD; p = 0.011). There also seemed to be an association that those with the presence of advanced disease may have been more likely to complete therapy (node positive disease at the time of diagnosis, p = 0.07).</p><p><strong>Limitations: </strong>It is a retrospective study and has to rely on physician notes for the subjective data. For the survival analyses, the median follow-up times for both of the groups were less than 3.5 years.</p><p><strong>Conclusions: </strong>Younger patients were more likely to complete therapy. There was a trend towards an association between more advanced disease and the completion of therapy. Most common causes of discontinuation of therapy were fatigue, fever, depression, and nausea.</p>\",\"PeriodicalId\":45335,\"journal\":{\"name\":\"Journal of Experimental Therapeutics and Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Experimental Therapeutics and Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Experimental Therapeutics and Oncology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

导言:干扰素α2B(IFN-α)治疗恶性黑色素瘤提高了无复发生存率和总生存率,但毒性很大,而且大大降低了整体生活质量(QoL)。相当多的患者没有完成整个疗程(一年):本研究旨在评估患者对 IFN-α 治疗的耐受能力,并将我们的结果与文献报道的数据进行比较:我们对确诊为皮肤恶性黑色素瘤并在手术切除后接受 IFN 治疗的患者进行了回顾性研究。患者分为两组:完成治疗的患者(CIT)和未完成治疗的患者(未完成治疗,IIT)。计算治疗持续时间。报告中止治疗的原因和副作用。统计学意义以 p &#60; 0.05 为标准:共有 64 名患者被纳入审查范围。有 16 名患者(25%)完成了治疗。中断 IFN-α 治疗的最常见原因是疲劳(81.3%)、发热(40.6%)、抑郁(28.1%)和恶心(18.8%)。CIT 组患者比 IIT 组患者年轻(47.4 ± 14.2 岁 vs 57.8 ± 11.9 岁,平均 ± SD;P = 0.011)。此外,晚期患者似乎更有可能完成治疗(诊断时结节阳性,p = 0.07):这是一项回顾性研究,主观数据必须依靠医生的记录。在生存分析中,两组患者的中位随访时间均不足3.5年:结论:年轻患者更有可能完成治疗。结论:年轻患者更有可能完成治疗,晚期疾病与完成治疗之间存在关联。中断治疗的最常见原因是疲劳、发烧、抑郁和恶心。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
A retrospective analysis of tolerance and outcomes of cutaneous malignant melanoma in patients receiving adjuvant interferon-alpha 2B: a community oncology perspective.

Introduction: Interferon alpha 2B (IFN-α) therapy in malignant melanoma has improved relapse free survival and overall survival but is considerably toxic and lowers the overall quality of life (QoL) substantially. A significant number of patients do not complete the full duration (one year) of therapy.

Objective: The aim of this study was to evaluate patients' ability to tolerate IFN-α therapy and to compare our results to reported data in the literature.

Methods: We conducted a retrospective review of patients diagnosed with cutaneous malignant melanoma who received IFN therapy after surgical resection. Patients were divided into two groups: patient who completed therapy (CIT) and those who did not (incomplete therapy, IIT). Duration of therapy was calculated. Reason for discontinuation and experienced side effects were reported. Statistical significance was determined at p &#60; 0.05.

Results: A total of 64 patients were included in the review. There were 16 (25%) patients were able to complete therapy. The most common reasons for discontinuing IFN-α therapy was fatigue (81.3%), fever (40.6%), depression (28.1%) and nausea (18.8%). Patients in the CIT group were younger than those in the IIT group (47.4 ± 14.2 vs 57.8 ± 11.9 years, mean ± SD; p = 0.011). There also seemed to be an association that those with the presence of advanced disease may have been more likely to complete therapy (node positive disease at the time of diagnosis, p = 0.07).

Limitations: It is a retrospective study and has to rely on physician notes for the subjective data. For the survival analyses, the median follow-up times for both of the groups were less than 3.5 years.

Conclusions: Younger patients were more likely to complete therapy. There was a trend towards an association between more advanced disease and the completion of therapy. Most common causes of discontinuation of therapy were fatigue, fever, depression, and nausea.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Giant Cervicodorsal Schwannoma. Clear cell variant of Oral Squamous cell carcinoma. Cervical carcinosarcoma presented in advanced stage after high grade cervical displasia. Glandular odontogenic cyst: a case report in an asymptomatic patient. Mebendazole in simultaneous combination with dexamethasone-(C21-phosphoramidate)-[anti-EGFR] generated utilizing a novel synthesis regimen: dual anti-neoplastic cytotoxicity against pulmonary adenocarcinoma (A549).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1